公开(公告)号：EP0755684B1

公开(公告)日：2001-04-25

申请号：EP96111909.6

申请日：1990-10-01

Applicant: UNIVERSITY OF ARKANSAS

Inventor： Whitfill, Craig E. ,  Fredericksen, Tommy L. ,  Tyczkowski, Julius K. ,  Thaxton, James Paul, Jr. ,  Thoma, John A., Dr.

IPC: A61K39/42 ,  A61K39/12 ,  A61K39/00 ,  A61K35/14 ,  B65D35/14

CPC classification number: C07K16/1036 ,  A61K38/00 ,  A61K39/00 ,  A61K39/12 ,  A61K2039/505 ,  A61K2039/525 ,  A61K2039/552 ,  C07K16/08 ,  C07K16/081 ,  C12N2720/10034 ,  Y10S435/948

公开(公告)号：EP0835124A1

公开(公告)日：1998-04-15

申请号：EP96920129.0

申请日：1996-05-03

Applicant: Viro Tech Limited Partnership

Inventor： HOWARD, Mark, E.

IPC: A61K9 ,  A61K35 ,  A61K39 ,  A61K47 ,  A61P31 ,  A61P35 ,  C07K16 ,  A61K38

CPC classification number: C07K16/065 ,  A61K38/00 ,  A61K39/39516 ,  C07K16/1036

Abstract: Serum and immunoglobulin preparations obtained from sharks are used to prepare compositions, including pharmaceutical compositions, for inhibiting retrovirus replication in susceptible cells. Thus, the serum preparations are useful for inhibiting diseases associated with retroviral infection, such as acquired immunodeficiency syndrome. The serum concentrates and immunoglobulins therefrom are also used to inhibit growth of tumor cells, especially sarcomas and leukemias.

公开(公告)号：EP0556327A4

公开(公告)日：1994-08-31

申请号：EP92901142

申请日：1991-11-06

Applicant: VERIGEN, INC.

Inventor： OSTHER, KURT, D. M.D. ,  KELLERMANN, GOTTFRIED, H.

IPC: A61K35/74 ,  A61K35/76 ,  C07K16/08 ,  C07K16/10 ,  C07K16/12 ,  C07K16/20 ,  G01N33/53 ,  G01N33/569 ,  G01N33/574 ,  A61K35/16

CPC classification number: C07K16/20 ,  C07K16/081 ,  C07K16/1036 ,  C07K16/12

公开(公告)号：EP0546126A4

公开(公告)日：1993-07-21

申请号：EP92904738

申请日：1991-08-29

Applicant: THE WISTAR INSTITUTE OF ANATOMY & BIOLOGY

Inventor： DEFREITAS, ELAINE ,  HILLIARD, BRENDAN

IPC: A61K39/12 ,  A61K39/00 ,  A61P31/12 ,  C07K14/00 ,  C07K14/005 ,  C07K14/15 ,  C07K14/195 ,  C07K16/00 ,  C07K16/10 ,  C12N5/10 ,  C12N7/00 ,  C12N15/09 ,  C12N15/48 ,  C12P21/08 ,  C12Q1/68 ,  C12Q1/70 ,  G01N33/53 ,  G01N33/569 ,  A61K35/14 ,  C07H15/12 ,  C07K3/00 ,  C12N5/00 ,  C12N15/00 ,  C12Q1/00

CPC classification number: C07K14/005 ,  A61K39/00 ,  C07K16/1036 ,  C12N2740/13022 ,  C12Q1/6883 ,  C12Q1/702

公开(公告)号：EP0406557A2

公开(公告)日：1991-01-09

申请号：EP90109892.1

申请日：1990-05-23

Applicant: SANDOZ LTD. ,  DUKE UNIVERSITY

Inventor： Bachmayer, Helmut, ,  Boehnlein, Ernst, ,  Cullen, Bryan R., ,  Greene, Warner C., ,  Hauber, Joachim,

IPC: C12N15/49 ,  C12P21/02 ,  A61K39/21 ,  A61K48/00

CPC classification number: C07K16/1036 ,  A61K38/00 ,  C07K14/005 ,  C12N2740/14022 ,  C12N2740/16322

Abstract: Transdominant repressors of viral gene phenotypic expression derived from the rev gene product of HIV-1 or the rex gene product of HTLV-1 and corresponding mutated genes are described', having the capability of repressing the Rev function in HIV-1 and/or the Rex function in HTLV-I and HTLV-II. Transient gene expression analysis of a series of missense and deletion mutants has been used.
Some of the mutants found repress both the Rev and the Rex function and are thus active in more than one viral species.
Transdominant viral mutants represent a promising new class of anti-viral agents. Cellular expression of these transdominant inhibitors may be used in such therapeutic approaches as intracellular immunization in order to protect cells against the deleterious effects of viral, e.g. HIV-1 infection.

Abstract translation: 描述了源自HIV-1的rev基因产物或HTLV-1的rex基因产物及相应的突变基因的病毒基因表型表达的显性阻遏物，具有抑制HIV-1和/或 HTLV-I和HTLV-II中的Rex功能。 已经使用了一系列错义和缺失突变体的瞬时基因表达分析。 一些突变体发现抑制Rev和Rex功能，因此在多种病毒物种中活跃。 横向显性病毒突变体代表了一种有希望的新类型的抗病毒剂。 这些跨主要抑制剂的细胞表达可以用于这样的治疗方法，如细胞内免疫，以保护细胞免受病毒的有害影响，例如， HIV-1感染。

公开(公告)号：WO2016198852A1

公开(公告)日：2016-12-15

申请号：PCT/GB2016/051683

申请日：2016-06-08

Applicant: SWANSEA UNIVERSITY

Inventor： DYSON, Paul ,  WHITTEN, Miranda

IPC: C12R1/01 ,  A01N63/00 ,  C12N15/113 ,  C12N15/82

CPC classification number: C12R1/01 ,  A01N25/006 ,  A01N37/46 ,  A01N63/00 ,  A01N63/02 ,  C07K16/1036 ,  C12N15/113 ,  C12N15/746 ,  C12N2310/14

Abstract: The invention relates to a genetically transformed or transfected bacterial cell of a gut symbiont of an insect belonging to the Order Thysanoptera wherein said cell is transformed to express double-stranded RNA (dsRNA) active against at least one selected insect gene; a vector for transforming or transfecting said bacterial cell; an insect including said transformed bacterial cell and a method of pest control employing the use of said bacterial cell and/or said insect.

Abstract translation: 本发明涉及一种遗传转化或转染的属于缨翅目蛾类昆虫的肠共生体的细菌细胞，其中所述细胞被转化以表达对至少一种选择的昆虫基因具有活性的双链RNA（dsRNA）; 用于转化或转染所述细菌细胞的载体; 包括所述转化的细菌细胞的昆虫和使用所述细菌细胞和/或所述昆虫的害虫防治方法。

公开(公告)号：WO2010138803A3

公开(公告)日：2011-04-21

申请号：PCT/US2010036554

申请日：2010-05-28

Applicant: UNIV TEXAS ,  WANG-JOHANNING FENG

Inventor： WANG-JOHANNING FENG

IPC: C07K16/30 ,  A61K39/395 ,  A61P35/00 ,  G01N33/574

CPC classification number: C07K16/1036 ,  A61K39/0011 ,  A61K47/6839 ,  A61K47/6855 ,  A61K47/6865 ,  A61K47/6869 ,  A61K2039/505 ,  C07K16/3015 ,  C07K16/3053 ,  C07K16/3069 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/77 ,  C07K2319/55 ,  C12N2740/10011 ,  G01N33/57407 ,  G01N33/57415 ,  G01N33/57434 ,  G01N33/57449 ,  G01N33/57484 ,  G01N33/57492

Abstract: Methods and compositions for cancer diagnostics and therapy are provided. More particular, methods and compositions for detecting, preventing, and treating HERV-K+ cancers are provided. One example of a method may involve a method for preventing or inhibiting cancer cell proliferation by administering to a subject a cancer cell proliferation blocking or reducing amount of a HERV-K env protein binding antibody.

Abstract translation: 提供了癌症诊断和治疗的方法和组合物。 提供了更具体的用于检测，预防和治疗HERV-K +癌症的方法和组合物。 方法的一个实例可以涉及通过向受试者施用癌细胞增殖阻断或减少HERV-K env蛋白结合抗体的量来预防或抑制癌细胞增殖的方法。

公开(公告)号：WO2010059876A2

公开(公告)日：2010-05-27

申请号：PCT/US2009/065217

申请日：2009-11-19

Applicant: CALIFORNIA INSTITUTE OF TECHNOLOGY ,  LUO, Xin ,  YANG, Lili ,  BALTIMORE, David

Inventor： LUO, Xin ,  YANG, Lili ,  BALTIMORE, David

IPC: C12N5/0781 ,  C12N5/0789

CPC classification number: C12N5/0635 ,  C07K16/00 ,  C07K16/1036 ,  C07K16/1045 ,  C12N2501/056 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/22 ,  C12N2501/23 ,  C12N2501/26 ,  C12N2501/52 ,  C12N2502/1394 ,  C12N2510/02

Abstract: The present disclosure relates to systems, methods and compositions for the generation of antibody-producing B cells in vitro. Some embodiments are related to an in vitro system for generating antibody-producing B cells from hematopoietic stem/progenitor cells (HSPCs).

Abstract translation: 本公开涉及用于在体外产生产生抗体的B细胞的系统，方法和组合物。 一些实施方案涉及用于从造血干细胞/祖细胞（HSPC）产生产生抗体的B细胞的体外系统。

公开(公告)号：WO2009036063A1

公开(公告)日：2009-03-19

申请号：PCT/US2008/075853

申请日：2008-09-10

Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES ,  NABEL, Gary, J. ,  YANG, Zhi-yong

Inventor： NABEL, Gary, J. ,  YANG, Zhi-yong

IPC: C12N15/867 ,  C12Q1/70 ,  G01N33/569 ,  A61K39/145

CPC classification number: C07K16/1036 ,  A61K2039/5256 ,  A61K2039/53 ,  C07K14/005 ,  C12N9/6408 ,  C12N15/86 ,  C12N2740/13045 ,  C12N2740/15043 ,  C12N2740/15045 ,  C12N2760/16122 ,  C12N2760/16134 ,  C12N2810/6072 ,  C12Q1/18 ,  G01N33/56983 ,  G01N2333/11

Abstract: Novel recombinant pseudotyped lentiviral or retroviral vectors comprising a nucleic acid encoding hemagglutinin, a nucleic acidneuraminidase and a nucleic acid a protease capable of cleaving a plurality of HA subtypes to their fusion-active form are useful in a variety of methods including methods for determining the effectiveness of vaccine-mediated immune response, methods for detecting the potency of neutralizing monoclonal antibodies, methods for detecting a compound that affects HA-mediated viral entry into a cell, methods for determining receptor specificity, methods for detecting an influenza infection. In addition, recombinant pseudotyped lentiviral or retroviral vectors comprising a nucleic acid encoding hemagglutinin without a nucleic acid encoding a protease and associated methods are also contemplated.

Abstract translation: 包含编码血细胞凝集素，核酸神经氨酸酶和核酸的能够将多个HA亚型切割成其融合活性形式的蛋白酶的新型重组假型慢病毒或逆转录病毒载体可用于多种方法，包括确定有效性的方法 疫苗介导的免疫应答的检测方法，用于检测中和单克隆抗体效力的方法，用于检测影响HA介导的病毒进入细胞的化合物的方法，用于确定受体特异性的方法，检测流感感染的方法。 此外，还考虑了包含编码没有编码蛋白酶的核酸和相关方法的血凝素的核酸的重组假型慢病毒或逆转录病毒载体。

公开(公告)号：WO2008142157A1

公开(公告)日：2008-11-27

申请号：PCT/EP2008/056359

申请日：2008-05-23

Applicant: AVIR GREEN HILLS RESEARCH DEVELOPMENT TRADE AG ,  HUMER, Johannes ,  MAYER, Bernd ,  MUSTER, Thomas ,  WALTENBERGER, Andrea

Inventor： HUMER, Johannes ,  MAYER, Bernd ,  MUSTER, Thomas ,  WALTENBERGER, Andrea

IPC: C07K16/10 ,  C07K16/30 ,  A61K39/395 ,  A61P35/00 ,  G01N33/574 ,  G01N33/577

CPC classification number: C07K16/1036 ,  A61K2039/505 ,  C07K16/3053 ,  C07K2317/34 ,  C07K2317/73 ,  C07K2317/732

Abstract: The present invention provides antibodies, or fragments thereof, for isolating and/or identifying epitopes of an endogenous retrovirus, preferably of a melanoma associated endogenous retrovirus, and hybridoma cells producing said antibodies. The antibodies are useful especially for the treatment and diagnosis of cancer. Further, the present application covers diagnostic kits for the detection of cancer cells, especially of melanoma cells and methods for cancer diagnosis using said antibodies.

Abstract translation: 本发明提供用于分离和/或鉴定内源性逆转录病毒，优选黑素瘤相关内源性逆转录病毒的表位的抗体或其片段，以及产生所述抗体的杂交瘤细胞。 抗体特别适用于癌症的治疗和诊断。 此外，本申请包括用于检测癌细胞，特别是黑素瘤细胞的诊断试剂盒和使用所述抗体的癌症诊断方法。